Volm M, Koomägi R, Mattern J, Efferth T
German Cancer Research Centre, Heidelberg, Germany.
Br J Cancer. 2002 Jul 29;87(3):251-7. doi: 10.1038/sj.bjc.6600463.
Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of 94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression profile of non-small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis revealed three different resistance profiles. The frequency of each profile was different (77, 14 and 9%, respectively). In the most frequent drug resistance profile, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase, glutathione-S-transferase-pi, metallothionein, O6-methylguanine-DNA-methyltransferase and major vault protein/lung resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance profile, FOS was up-regulated and NM23 down-regulated. In the second profile, only three resistance proteins were increased (glutathione-S-transferase-pi, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic factors were reduced. In the third profile, only five of the resistance factors were increased (MDR1, thymidylate-synthetase, glutathione-S-transferase-pi, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein).
从多个来源获得的数据表明,没有单一机制能够解释非小细胞肺癌对化疗的耐药性。耐药性的多因素性质意味着,与单基因或蛋白质表达研究相比,对组成表达谱的分析可能会更准确地预测耐药性。主要通过免疫组织化学方法对94例原发性非小细胞肺癌患者标本中的40个细胞参数(耐药蛋白、增殖、凋亡和血管生成因子、原癌基因产物和抑癌基因)进行了评估,并与肿瘤在体外对阿霉素的反应进行了比较。通过层次聚类分析和聚类图像映射确定了非小细胞肺癌的蛋白质表达谱。聚类分析揭示了三种不同的耐药谱。每种谱的频率不同(分别为77%、14%和9%)。在最常见的耐药谱中,耐药蛋白P-糖蛋白/MDR1(MDR1,ABCB1)、胸苷酸合成酶、谷胱甘肽-S-转移酶-pi、金属硫蛋白、O6-甲基鸟嘌呤-DNA甲基转移酶和主要穹窿蛋白/肺耐药相关蛋白上调。微血管密度、血管生成因子血管内皮生长因子及其受体FLT1以及ECGF1也下调。此外,与敏感的非小细胞肺癌相比,增殖因子增殖细胞核抗原和细胞周期蛋白A减少。在这种耐药谱中,FOS上调而NM23下调。在第二种谱中,只有三种耐药蛋白增加(谷胱甘肽-S-转移酶-pi、O6-甲基鸟嘌呤-DNA甲基转移酶、主要穹窿蛋白/肺耐药相关蛋白)。血管生成因子减少。在第三种谱中,只有五种耐药因子增加(MDR1、胸苷酸合成酶、谷胱甘肽-S-转移酶-pi、O6-甲基鸟嘌呤-DNA甲基转移酶、主要穹窿蛋白/肺耐药相关蛋白)。